These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29784433)

  • 1. FDA and NIST collaboration on standards development activities supporting innovation and translation of regenerative medicine products.
    Arcidiacono JA; Bauer SR; Kaplan DS; Allocca CM; Sarkar S; Lin-Gibson S
    Cytotherapy; 2018 Jun; 20(6):779-784. PubMed ID: 29784433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine.
    Witten CM; McFarland RD; Simek SL
    Stem Cells Transl Med; 2015 Dec; 4(12):1495-9. PubMed ID: 26494784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020?
    Fang WH; Vangsness CT
    Arthroscopy; 2020 Oct; 36(10):2765-2770. PubMed ID: 32442713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manufacturing road map for tissue engineering and regenerative medicine technologies.
    Hunsberger J; Harrysson O; Shirwaiker R; Starly B; Wysk R; Cohen P; Allickson J; Yoo J; Atala A
    Stem Cells Transl Med; 2015 Feb; 4(2):130-5. PubMed ID: 25575525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
    Nagai S
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Navani A; Manchikanti L; Albers SL; Latchaw RE; Sanapati J; Kaye AD; Atluri S; Jordan S; Gupta A; Cedeno D; Vallejo A; Fellows B; Knezevic NN; Pappolla M; Diwan S; Trescot AM; Soin A; Kaye AM; Aydin SM; Calodney AK; Candido KD; Bakshi S; Benyamin RM; Vallejo R; Watanabe A; Beall D; Stitik TP; Foye PM; Helander EM; Hirsch JA
    Pain Physician; 2019 Jan; 22(1S):S1-S74. PubMed ID: 30717500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?
    Yano K; Speidel AT; Yamato M
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1579-1593. PubMed ID: 29702746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The implications of "advanced therapies" regulation.
    Sethe SC
    Rejuvenation Res; 2010; 13(2-3):327-8. PubMed ID: 20462386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regenerative medicine and responsible research and innovation: proposals for a responsible acceleration to the clinic.
    Webster A
    Regen Med; 2017 Oct; 12(7):853-864. PubMed ID: 29094647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Institutional profile. The International Society for Cellular Therapy: evolving to meet the demands of the regenerative medicine industry.
    Maziarz RT; Arthurs J; Horwitz E
    Regen Med; 2011 Mar; 6(2):163-6. PubMed ID: 21391849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standards efforts and landscape for rapid microbial testing methodologies in regenerative medicine.
    Lin-Gibson S; Lin NJ; Jackson S; Viswanathan S; Zylberberg C; Wolfrum J; Basu S; Roy K; Marshall D; McFarland R; Hoover S; Rietze R; Getz A; Henke D
    Cytotherapy; 2021 May; 23(5):390-398. PubMed ID: 33775524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there specific translational challenges in regenerative medicine? Lessons from other fields.
    Gardner J; Faulkner A; Mahalatchimy A; Webster A
    Regen Med; 2015; 10(7):885-95. PubMed ID: 26541074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FDA approval process for medical devices: an inherently flawed system or a valuable pathway for innovation?
    Fargen KM; Frei D; Fiorella D; McDougall CG; Myers PM; Hirsch JA; Mocco J
    J Neurointerv Surg; 2013 Jul; 5(4):269-75. PubMed ID: 22764203
    [No Abstract]   [Full Text] [Related]  

  • 17. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
    Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summary of the National Institute of Standards and Technology and US Food And Drug Administration cell counting workshop: Sharing practices in cell counting measurements.
    Lin-Gibson S; Sarkar S; Elliott JT
    Cytotherapy; 2018 Jun; 20(6):785-795. PubMed ID: 29699860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological Products: Cellular Therapy and FDA Approved Products.
    Golchin A; Farahany TZ
    Stem Cell Rev Rep; 2019 Apr; 15(2):166-175. PubMed ID: 30623359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, Entrepreneurs, and Industry.
    Bock AJ; Johnson D
    Adv Exp Med Biol; 2018; 1098():213-236. PubMed ID: 30238374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.